Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 2/20 | 0.57 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.47 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.47 |
| ▸ | CDK2 | P24941 | 2/20 | 0.47 |
| ▸ | CDK9 | P50750 | 2/20 | 0.47 |
| ▸ | IGF1R | P08069 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 6/20 | 0.43 |
| ▸ | SGK1 | O00141 | 5/20 | 0.43 |
| ▸ | AXL | P30530 | 6/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8318330 | 0.88 | CDK8 (0.58) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8314436 | 0.87 | CDK8 (0.59) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8313356 | 0.86 | CDK8 (0.56) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13745336 | 0.86 | CDK8 (0.61) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13745546 | 0.84 | CDK8 (0.56) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8316526 | 0.83 | CDK8 (0.71) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13746026 | 0.83 | CDK8 (0.64) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8320558 | 0.82 | CDK8 (0.64) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL8317282 | 0.81 | CDK8 (0.59) | CDK8CCNT1CCNA2CDK2CDK9 | |
| SCHEMBL13746094 | 0.80 | CDK8 (0.51) | CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-20090215771-A1 | JNK INHIBITORS | GRACZYK PIOTR | 2009-08-27 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432375-B2 | JNK inhibitors | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2008-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215771-A1 | JNK INHIBITORS | MAPKAPK2, MAPK1, MAPKAPK3 | CDK8 360/4885CCNT1 1186/4885CCNA2 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.